Our study confirms and expands these exploratory findings with robust data on bleeding in an unselected cohort of consecutive cancer patients, particularly as GDF-15 levels were not predictive of major bleeding in the placebo group of the AVERT trial. The gene discussed is GDF15; the disease is cancer.